SecBot SecBot
S-3ASR ·Filed Nov 9, 2026

IMNM

Immunome Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed7d 9h ago SEC0001193125-26-453803
Notable filing: S-3ASR
Actionable Insight • Neutral

The shelf filing itself is not an immediate dilutive event. Monitor subsequent prospectus supplements and ATM sales disclosures for actual share issuance. The concurrent 10-Q shows adequate cash runway into 2028, reducing the likelihood of an urgent capital raise.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

IMNM drug pipeline →

varegacestat

▲ Bullish Named in this S-3ASR
Impact
Phase
Filed/PDUFA
Time to market
FDA PDUFA target action date is April 28, 2027. EMA review is also underway following MAA validation in October 2026. If approved, varegacestat could launch in the US in the second half of 2027.
Next catalyst
PDUFA date · Apr 28, 2027 162d

What to watchThe single most important catalyst is the FDA PDUFA decision on April 28, 2027. Approval would make varegacestat the second FDA-approved therapy for desmoid tumors and unlock a meaningful commercial opportunity, while a Complete Response Letter would severely pressure the stock given the company's pre-revenue status and reliance on this asset. Watch for EMA review progress and Q3 earnings on November 16 for pipeline updates and cash runway details.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$18.65
T+0 close · Nov 9, 2026 · via day close
Latest settled
+2.25%
T+1 · $19.07 · next T+5 in 4h
Vs SPY
+0.93%
α at T+1
Latest observation
−1.66%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $18.65entry
  2. T+1 · 6d ago +2.25%α +0.93% · $19.07
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immunome filed an automatic shelf registration (S-3ASR) as a well-known seasoned issuer, including an ATM sales agreement prospectus for up to $134.1 million of common stock through TD Cowen. The company had $461.6 million in cash and securities as of September 30, 2026, with a cash runway into 2028, suggesting this is an opportunistic shelf filing rather than a distress-driven capital raise.

Key Facts

  • S-3ASR filed as a well-known seasoned issuer with no limit on aggregate securities offered under the base prospectus
  • ATM sales agreement prospectus for up to $134.1 million of common stock through TD Cowen
  • Prior ATM agreement had $200M authorization; $65.9M in gross proceeds raised from 6,655,587 shares sold under prior ATM
  • Cash and securities totaled $461.6M as of September 30, 2026, down from $582.7M at Q1 end
  • Cash runway projected into 2028 per the 10-Q filed concurrently
  • PDUFA target action date of April 28, 2027 for varegacestat (desmoid tumors)
  • 113,647,456 shares outstanding as of September 30, 2026

Financial Impact

Up to $134.1 million in potential gross proceeds from ATM sales; no immediate dilution as no shares are sold at filing

dilutioncash

Risk Factors

  • Potential dilution from future ATM sales of up to $134.1 million
  • Cash burn rate: cash and securities declined $121.1M from Q1 to Q3 2026
  • Accumulated deficit of $940.9M as of September 30, 2026
  • Short interest of 17.3M shares (~14.6% of estimated shares outstanding)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
S-3ASR Filing (Primary)0001193125-26-453803
Document: d137036dex47.htm0001193125-26-453803

Track record

20 reports on IMNM

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
  2. Nov 9, 20267d ago S-3ASR Neutral 3/10 Viewing Entry $18.65 Now $17.61 −5.58% settles Feb 8
  3. Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
  4. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
  5. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
  6. Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
  7. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
  8. Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
  9. Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
  10. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026